Research analysts at StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) in a research report issued to clients and investors on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Performance
GLMD remained flat at $0.39 during trading on Thursday. The company had a trading volume of 22,429 shares, compared to its average volume of 261,749. The firm’s fifty day moving average price is $0.36 and its 200-day moving average price is $0.38. Galmed Pharmaceuticals has a 52-week low of $0.26 and a 52-week high of $7.80.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last posted its quarterly earnings results on Thursday, April 4th. The biopharmaceutical company reported ($0.98) earnings per share for the quarter.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Featured Articles
- Five stocks we like better than Galmed Pharmaceuticals
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- MarketBeat Week in Review – 4/29 – 5/3
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- What Are the U.K. Market Holidays? How to Invest and Trade
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
